Barry Greene was interested in pursuing opportunities related to central nervous system diseases when the long-time Alnylam Pharmaceuticals Inc. president made the decision to move on. Already familiar with Sage Therapeutics, Inc. and unable to take a long vacation between executive gigs due to the COVID-19 pandemic, Greene told Scrip, the opportunity to lead CNS drug developer Sage as its new CEO was a “no-brainer” – pun intended.
Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO
Jeff Jonas Remains As Chief Innovation Officer, Board Member
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
More from Leadership
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
More from Scrip
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.